• DOI:10.1007/s00702-008-0136-2
Corpus ID: 20716896

Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial

@article{Kessler2008EffectOC,
  title={Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial},
  author={H. Kessler and F. Pajonk and D. Bach and T. Schneider-Axmann and P. Falkai and W. Herrmann and G. Multhaup and J. Wiltfang and S. Schaefer and O. Wirths and T. Bayer},
  journal={Journal of Neural Transmission},
  year={2008},
  volume={115},
  pages={1651-1659}
}

H. Kessler, F. Pajonk, +8 authors T. Bayer

Published 2008

Psychology, Medicine

Journal of Neural Transmission

A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer’s disease (AD). In the present report we evaluated the efficacy of oral Cu supplementation on CSF biomarkers for AD. In a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial (12 months long) patients with mild AD received either Cu-(II)-orotate-dihydrate (verum group; 8 mg Cu daily) or placebo (placebo group). The primary outcome measures in CSF were Aβ42, Tau and Phospho-Tau. The… CONTINUE READING

View on Springer

link.springer.com

Save to Library

Create Alert

Cite

Launch Research Feed